Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed and Bevacizumab in Recurrent/Metastatic Head and Neck Cancer
NCT00222729Phase 2Completed
- Sponsor
- University of Pittsburgh
- Start
- Nov 2005
- Primary completion
- Oct 2013
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pemetrexed, bevacizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by University of Pittsburgh. Started Nov 2005; status: completed.
02
Drugs
pemetrexedbevacizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00222729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00222729.